➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
McKesson
Harvard Business School
Boehringer Ingelheim
Moodys

Last Updated: October 20, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR COAGULATION FACTOR IX (HUMAN)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for coagulation factor ix (human)

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000463 Post Coronary Artery Bypass Graft (CABG) Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1987-04-01 To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously.
NCT00000529 Tamoxifen Study Completed National Cancer Institute (NCI) Phase 3 1992-05-01 To assess the impact of tamoxifen on development of breast cancer, coronary heart disease, and bone fractures. The National Cancer Institute initiated the prevention trial under its National Surgical Adjuvant Breast and Bowel Project (NSABP). The National Heart, Lung, and Blood Institute provided support to obtain blood pressure and lipid measurements, and lipoprotein and selected coagulation factor measurements in a subsample.
NCT00000529 Tamoxifen Study Completed NSABP Foundation Inc Phase 3 1992-05-01 To assess the impact of tamoxifen on development of breast cancer, coronary heart disease, and bone fractures. The National Cancer Institute initiated the prevention trial under its National Surgical Adjuvant Breast and Bowel Project (NSABP). The National Heart, Lung, and Blood Institute provided support to obtain blood pressure and lipid measurements, and lipoprotein and selected coagulation factor measurements in a subsample.
NCT00000534 Calcium for Pre-Eclampsia Prevention (CPEP) Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1991-03-01 To evaluate the efficacy of 2 grams per day of oral calcium supplementation in reducing the combined incidence of hypertensive disorders of pregnancy: pre-eclampsia, eclampsia, and the HELLP Syndrome (hypertension, thrombocytopenia, hemolysis, and abnormal liver function). The National Institute of Child Health and Human Development (NICHD) initiated the trial in 1991, with joint funding provided by the National Heart, Lung, and Blood Institute in fiscal years 1992, 1993, and 1995.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for coagulation factor ix (human)

Condition Name

Condition Name for coagulation factor ix (human)
Intervention Trials
Healthy 27
Venous Thromboembolism 18
Atrial Fibrillation 18
Hemophilia A 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for coagulation factor ix (human)
Intervention Trials
Hemorrhage 70
Thrombosis 41
Blood Coagulation Disorders 41
Hemostatic Disorders 41
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for coagulation factor ix (human)

Trials by Country

Trials by Country for coagulation factor ix (human)
Location Trials
United States 665
Canada 126
China 106
Germany 67
Australia 62
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for coagulation factor ix (human)
Location Trials
California 46
Texas 44
Pennsylvania 40
New York 36
North Carolina 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for coagulation factor ix (human)

Clinical Trial Phase

Clinical Trial Phase for coagulation factor ix (human)
Clinical Trial Phase Trials
Phase 4 201
Phase 3 152
Phase 2/Phase 3 31
[disabled in preview] 178
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for coagulation factor ix (human)
Clinical Trial Phase Trials
Completed 353
Recruiting 188
Not yet recruiting 160
[disabled in preview] 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for coagulation factor ix (human)

Sponsor Name

Sponsor Name for coagulation factor ix (human)
Sponsor Trials
Boehringer Ingelheim 22
National Cancer Institute (NCI) 19
Bayer 19
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for coagulation factor ix (human)
Sponsor Trials
Other 995
Industry 302
NIH 55
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKinsey
Johnson and Johnson
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.